Back to Market News

MedservRegis plc – Distribution of Bond Issue

cyber

October 10, 2025

Market News
10 October, 2025
2 min read
Market News
10 October, 2025
2 min read

Following last week's article detailing the performance of the S&P 500 index in 2025, it is worth devoting time to review the developments across the European equity markers in my last article of the year.

On 10 October 2025, MedservRegis plc announced that the Board of Directors approved the submission of an application to the Malta Financial Services Authority requesting admissibility to listing and trading of new bonds consisting of the Euro equivalent of €25 million in a mix of 5.50% euro-denominated unsecured bonds and 6.50% US Dollar denominated unsecured bonds maturing in 2031 – 2036.

Subject to regulatory approval, the bonds will be available for subscription by holders of the 4.5% euro-denominated unsecured bonds and the 5.75% US Dollar denominated unsecured bonds, both due for redemption on 5 February 2026, through an exchange offer. In this respect, the holders of these bonds as at close of trading on 14 October 2025 will have the option to exchange the bonds for an equivalent number of the new bonds by surrendering the existing bonds held. For the purposes of the exchange offer, Medserv submitted a request for the suspension of trading of the bonds maturing on 5 February 2026 with effect from 14 October 2025.

Any new bonds not subscribed for by existing bondholders shall be available for subscription through an intermediaries’ offer. Further details will be published once regulatory approval is obtained.

The article contains public information only and is published solely for informational purposes. It should not be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in this article. Rizzo, Farrugia & Co. (Stockbrokers) Ltd (“Rizzo Farrugia”) is under no obligation to update or keep current the information contained herein. Since the buying and selling of securities by any person is dependent on that person’s financial situation and an assessment of the suitability and appropriateness of the proposed transaction, no person should act upon any recommendation in this article without first obtaining investment advice. Rizzo Farrugia, its directors, the author of this article, other employees or clients may have or have had interests in the securities referred to herein and may at any time make purchases and/or sales in them as principal or agent. Furthermore, Rizzo Farrugia may have or have had a relationship with or may provide or has provided other services of a corporate nature to companies herein mentioned. Stock markets are volatile and subject to fluctuations which cannot be reasonably foreseen. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security mentioned in this article. Neither Rizzo Farrugia, nor any of its directors or employees accepts any liability for any loss or damage arising out of the use of all or any part of this article. Additional information can be made available upon request from Rizzo, Farrugia & Co. (Stockbrokers) Ltd., Airways House, Fourth Floor, High Street, Sliema SLM 1551. Telephone: +356 2258 3000; Email: info@rizzofarrugia.com; Website: www.rizzofarrugia.com © 2021 Rizzo, Farrugia & Co. (Stockbrokers) Ltd. All rights reserved. This article may not be reproduced or redistributed, in whole or in part, without the written permission of Rizzo Farrugia. Moreover, Rizzo Farrugia accepts no liability whatsoever for the actions of third parties in this respect.

This article was produced by Edward Rizzo, Director at Rizzo Farrugia, which is a company licensed to undertake investment services in Malta by the MFSA under the Investment Services Act, Cap. 370 of the Laws of Malta and a member of the Malta Stock Exchange. The company’s registered address is at Airways House, Fourth Floor, High Street, Sliema SLM 1551, Malta.

The article contains public information only and is published solely for informational purposes. It should not be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in this article. Rizzo, Farrugia & Co. (Stockbrokers) Ltd (“Rizzo Farrugia”) is under no obligation to update or keep current the information contained herein. Since the buying and selling of securities by any person is dependent on that person’s financial situation and an assessment of the suitability and appropriateness of the proposed transaction, no person should act upon any recommendation in this article without first obtaining investment advice. Rizzo Farrugia, its directors, the author of this article, other employees or clients may have or have had interests in the securities referred to herein and may at any time make purchases and/or sales in them as principal or agent. Furthermore, Rizzo Farrugia may have or have had a relationship with or may provide or has provided other services of a corporate nature to companies herein mentioned. Stock markets are volatile and subject to fluctuations which cannot be reasonably foreseen. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security mentioned in this article. Neither Rizzo Farrugia, nor any of its directors or employees accepts any liability for any loss or damage arising out of the use of all or any part of this article. Additional information can be made available upon request from Rizzo, Farrugia & Co. (Stockbrokers) Ltd., Airways House, Fourth Floor, High Street, Sliema SLM 1551. Telephone: +356 2258 3000; Email: info@rizzofarrugia.com; Website: www.rizzofarrugia.com © 2021 Rizzo, Farrugia & Co. (Stockbrokers) Ltd. All rights reserved. This article may not be reproduced or redistributed, in whole or in part, without the written permission of Rizzo Farrugia. Moreover, Rizzo Farrugia accepts no liability whatsoever for the actions of third parties in this respect.

This article was produced by Edward Rizzo, Director at Rizzo Farrugia, which is a company licensed to undertake investment services in Malta by the MFSA under the Investment Services Act, Cap. 370 of the Laws of Malta and a member of the Malta Stock Exchange. The company’s registered address is at Airways House, Fourth Floor, High Street, Sliema SLM 1551, Malta.

On 10 October 2025, MedservRegis plc announced that the Board of Directors approved the submission of an application to the Malta Financial Services Authority requesting admissibility to listing and trading of new bonds consisting of the Euro equivalent of €25 million in a mix of 5.50% euro-denominated unsecured bonds and 6.50% US Dollar denominated unsecured bonds maturing in 2031 – 2036.

Subject to regulatory approval, the bonds will be available for subscription by holders of the 4.5% euro-denominated unsecured bonds and the 5.75% US Dollar denominated unsecured bonds, both due for redemption on 5 February 2026, through an exchange offer. In this respect, the holders of these bonds as at close of trading on 14 October 2025 will have the option to exchange the bonds for an equivalent number of the new bonds by surrendering the existing bonds held. For the purposes of the exchange offer, Medserv submitted a request for the suspension of trading of the bonds maturing on 5 February 2026 with effect from 14 October 2025.

Any new bonds not subscribed for by existing bondholders shall be available for subscription through an intermediaries’ offer. Further details will be published once regulatory approval is obtained.